KRAS and pancreatic adenocarcinoma: We first performed overall survival analysis to compare the survival of patients harboring mutant or wildtype KRAS in pancreatic adenocarcinoma (PAAD), lung adenocarcinoma (LUAD), and colorectal adenocarcinoma (COAD).